First pill for postnatal depression set to save lives | UK | News
A new groundbreaking pill, greeted as “breakthrough için for postpartum depression, became the first treatment of the licensed species in the UK.
The drug, Zurzuvae ™ (zuranolone), when experts say, maternal mental health can mark a turning point in the drug regulator – Pharmaceutical and Health Products Regulatory Agency (MHRA) was given forward.
Postnatal Depression (PND) affects at least 1 out of 10 mothers. A recent report of the Royal Psychiatrists College further raised this figure and estimated that 85,000 mothers could only suffer from the PND last year.
Some of those affected take their own lives – about 25 mothers die with suicide after pregnancy or in the first year. Experts say that many cases are linked to PND. National Statistics Office data show that suicide is the leading cause of death in women during and after pregnancy.
So far, women have been forced to rely on conventional antidepressants or conventional antidepressants, which were ineffective or last to work six to twelve weeks or generally prescribed.
Essays show that Zurzuvae can improve symptoms as early as the third day of treatment. When taken once a day for a short course of 14 days, the brain moves on brain receptors and is thought to help balance the deteriorated nerve paths after birth.
Dr. Advisor Perinatal Psychiatrist Mano Manoharan said: “Postnatal depression… It affects not only mothers but also babies and families. Holistic, evidence -based treatments are vital.
NHS Advisor Psychiatrist Max Pemberton welcomed the news. He said: “The real tragedy is that women cannot get help very often, because they think they admit that they are unsuccessful. They are afraid of being tried, even fear that their baby will be taken.
“It is vital for women with postpartum depression not only for the sake of the sake of care, but also for their babies. Studies show that mothers with postnatal depression may struggle with attachment and stress hormone cortisol levels. These early experiences may have long -term effects.”
Studies have shown that each perinatal depression or anxiety is an average cost of £ 75,728, resulting from long -term effects on children. In one -year birth cohort, this is added more than 4.4 billion £.
Charities and clinicians welcomed the MHRA decision, but warned that the approval alone would not solve the problem.
Although the government promises to expand expert services, they say that new and pregnant mothers can still encounter a postal code lottery in the mental health presentation. Campaigns call Nice and NHS to ensure that Zurzuvae makes it as quickly existing and affordable as possible.
Mhra Temporary Executive Director Julian Beach said: “Keeping patients safe and accessing high quality, acceptable in an acceptable way to access safe and effective drugs are the main priorities for us.
“The approval of the zuranolone reflects our commitment to increase access to new drugs that have the potential to make a real difference for people suffering from serious health problems and recognized by comparable international regulators.
“We make sure that appropriate regulatory standards are met for the approval of this drug.
“As with all products, we will keep the safety of Zuranolone in close examination.”
